KS Insights: Phenotypic Drug Discovery скачать в хорошем качестве

KS Insights: Phenotypic Drug Discovery

About Keystone Symposia Insights Keystone Symposia Insights are panel discussions recorded on digital video that feature Keystone Symposia meeting organizers discussing the state of their respective fields. These thought leaders provide perspectives on current and future trends. The panel is asked to discuss the following topics: What is the state of this field? (What did we learn at the meeting?) Where is the field heading? What are the opportunities and challenges ahead? ___ Keystone Symposia Conference: Phenotypic Drug Discovery: Recent Advances and Insights from Chemical and Systems Biology (C1) Organizer(s) Mark Mercola, Fabien Vincent, Monica Schenone and Arsenio Nueda March 3—7, 2019 Beaver Run Resort • Breckenridge, Colorado USA Sponsored by Merck & Co., Inc. and Pfizer Inc. Unlike conventional target-centric drug discovery, Phenotypic Drug Discovery (PDD) places its focus on disease-relevant phenotypes and agnosticism with regard to molecular mechanism of action. Thus, it offers unique opportunities in terms of discovery of novel biology and first-in-class therapeutics but is matched with significant challenges, a number of which can be addressed by recent advances in chemical and systems biology. A key aspect of the conference will be to share information and processes on how best to employ phenotypic strategies to discover novel biology and effectively prosecute drug discovery programs. Specific topics will include: chemical biology advances and case studies in target identification; case studies of recently advanced clinical candidates and approved drugs; functional genomics and systems biology advances and case studies; project prosecution including lessons learned from lead optimization and pre-clinical development; complex cell-based models and new assay modalities. With few non-commercial meetings covering drug discovery as a discipline, this conference has the stature and breadth to bring together accomplished and influential scientists from industry and academia as demonstrated by the 2016 conference. Its scope will be broader than other PDD and Chemical Biology meetings since it will cover the entire range of activities and technologies from phenotypic assay systems, to target identification and FDA approval of novel therapeutics. Given that there is still an emphasis on target centric discovery in pharmaceutical companies, this conference can be instrumental in further promoting a shift in mindset and contributing to the consolidation of PDD as an integral part of the drug discovery paradigm. The vision for this conference would be to share success stories of newly approved drugs and late-stage clinical candidates, along with key lessons and best practices, to inform future PDD projects. ___ Copyright Keystone Symposia, 2019. All rights reserved. About Keystone Symposia: Keystone Symposia is a 501(c)(3) nonprofit organization founded in 1972 that convenes 50-60 open, international scientific research conferences each year across the full range of the life sciences – from cardiovascular disease to immunology to neurobiology. The conferences accelerate life science discovery by bringing together and fostering collaboration among the world’s leading and next generation of research scientists. Visit Keystone Symposia at: https://www.keystonesymposia.org Visit Virtual Keystone Symposia at: https://virtual.keystonesymposia.org/ For more videos:    / keystonesymposia   Follow us on Twitter:   / keystonesymp   Like us on Facebook:   / keystonesymposia   Link to us on LinkedIn: https://www.linkedin.com/company/1279...